In contrast, in diffuse large B-cell lymphoma, reduced ActA expression was found to correlate with reduced OS and PFS [32] and several malignancies, including breast and hepatocellular carcinoma, express high levels of ActA antagonists, such as follistatin and follistatin-like 3 [33,34]. The gene discussed is FSTL3; the disease is diffuse large B-cell lymphoma.